Urinary Tract Infection Testing Market

Urinary Tract Infection Testing Market Size

According to a recent study by Global Market Insights Inc., the global urinary tract infection testing market was valued at USD 1 billion in 2024 and is projected to grow from USD 1.1 billion in 2025 to USD 1.9 billion by 2034, expanding at a CAGR of 6.2%. The market is growing steadily stimulated by various factors, such as the rising global prevalence of urinary tract infections, growing incidence of hospital acquired urinary tract infection, high prevalence of diabetes in low and middle-income nations, and novel product launches regarding UTI testing.

Urinary tract infection (UTI) testing is a diagnostic process used to detect the presence of bacteria or other pathogens in a patient's urine that may cause infection in the urinary tract. UTIs are a common infection, particularly among women, and can cause discomfort, pain, and other health complications if left untreated. Major companies in the industry include Thermo Fisher Scientific, Randox Laboratories, F. Hoffmann-La Roche, Labcorp, and Siemens Healthineers.

The market increased from USD 866.8 million in 2021 to USD 990.3 million in 2023, primarily due to the rise in diabetes in low and middle-income countries during this period. For instance, in 2021, as per the statistics from the International Diabetes Federation (IDF), about 537 million adults aged between 20 and 79 years were living with diabetes. Furthermore, the rising number of type 1 diabetes patients, mainly children and adolescents, further propels the market growth since diabetic patients are highly prone to UTI. Therefore, as the prevalence of diabetes increases, so does the risk of developing UTI among diabetic patients, stimulating the need for advanced diagnostic testing, thereby positively contributing to the growth of the market.

The rising prevalence of urinary tract infections is one of the major catalysts for the growth of the urinary tract infection testing market. For instance, as per the data published in the American Journal of Kidney Disease, around 50% to 60% of women have at least one UTI in their lifetime. Moreover, according to the National Institutes of Health (NIH), urinary tract infections (UTIs) are a significant cause of illness, with 4.49 billion cases reported in 2021. UTIs are among the most common bacterial infections, affecting individuals across all age groups, but particularly prevalent among women, the elderly, and people with underlying health conditions.

Additionally, individuals suffering from diabetes are more prone to UTI infection. For instance, according to the 2022 data from the WHO, around 830 million people were living with diabetes. More than half of adults aged 30 years and over living with diabetes were not taking medication for their diabetes in 2022. Thus, as the prevalence of UTI and diabetes increases, so does the demand for effective and technologically advanced diagnostic tools such as urinary tract infection testing kits for accurate, timely diagnosis of the disease, and for proper medical intervention, thereby stimulating the adoption of these kits among the healthcare professionals, fostering the market growth.

Urinary tract infection (UTI) testing refers to the diagnostic procedures and methods employed to identify the presence of an infection in the urinary system. The urinary tract includes the kidneys, bladder, ureters, and urethra. UTIs are commonly caused by bacteria, such as Escherichia coli (E. coli), and can result in symptoms such as frequent and painful urination, cloudy or strong-smelling urine, and lower abdominal discomfort.

Urinary Tract Infection Testing Market Trends

• Hospital-acquired urinary tract infections (HAUTIs) are becoming more common, which is accelerating the growth of the market. These infections frequently occur in hospitals when patients use catheters for extended periods, undergo surgery, or have weakened immune systems. These infections contribute to increased patient morbidity and extended hospital stays.
  
• According to the Centers for Disease Control and Prevention (CDC), 75% of hospital-acquired UTIs are associated with urinary catheter use, and 15-25% of hospitalized patients receive urinary catheters during their hospital stay. Thus, this rising prevalence of hospital-acquired UTIs demonstrates the critical need for accurate and timely diagnostic tools for early infection detection and management, thereby propelling the market growth.
  
• Moreover, the increasing technological advancement in urinary tract infection testing kits is contributing to market growth. Several companies are investing in research and innovation for the development of technologically advanced UTI diagnostic kits.
  
• For instance, in September 2024, Mankind Pharma launched self-testing UTI kits, which offer private, quick, and reliable means of testing from the comfort of the home.
  
• Thus, such product innovation stimulates the adoption of the UTI kits among the individuals and healthcare professionals, positively contributing to the growth of the market.
  

Urinary Tract Infection Testing Market Analysis

The global market was valued at USD 866.8 million in 2021. The market size reached USD 990.3 million in 2023, from USD 952 million in 2022.

Based on the test type, the urinary tract infection testing market is segmented into urinalysis, urine cultures, and susceptibility testing. The urinalysis segment led this market in 2024, accounting for the highest market share owing to its cost-effectiveness, accessibility, and diagnostic efficacy. This segment was valued at USD 494.1 million in 2024 and is projected to reach USD 908.4 million by 2034, growing at a CAGR 6.3%. In comparison, the urine culture segment, valued at USD 347.2 million in 2024, is expected to grow to USD 647.4 million by 2034, with a slightly higher CAGR of 6.5%.

• Urinalysis test is widely recognized as the first-line diagnostic testing in healthcare to identify the bacteria responsible for UTI and guide potential treatment options for the individual suffering from the UTI.
  
• The growth of the segment is further accelerated by the rising aging population across the globe. UTI is more prevalent among the elderly population due to a combination of various psychological changes and increased medical interventions, such as indwelling catheters.
  
• For instance, according to data provided by the United Nations, it is projected that the global population aged 65 years and older will reach around 1.5 billion by 2050, representing 16% of the world's population. Moreover, according to data from the Population Reference Bureau, individuals in the U.S. aged 65 and older are projected to reach 82 million by 2050, up from 58 million in 2022.
  
• Thus, as the population ages, so does the risk of UTI infection among the elderly population, accelerating the demand for accurate and efficient non-invasive diagnostic tests such as urinalysis, positively contributing to the growth of the segment.
  
• Moreover, urinalysis is not only meant for diagnostic purposes but also for routine screening and preventive healthcare, assisting in the early diagnosis of asymptomatic UTIs, further fueling the segment's growth.
  

Based on test kit type, the urinary tract infection testing market is segmented into laboratory test kits and home test kits. The home test kits segment is anticipated to witness highest CAGR at 6.6% during the forecast period.

• Home test kits are designed to detect urinary tract infections (UTIs) in individuals from the comfort of their own homes. These tests typically use a dipstick or strip that is immersed in a urine sample, and the results are available within minutes.
  
• Moreover, technological advancements in home testing kits have enabled the development of accurate, easy-to-use test strips that deliver the results in a couple of minutes, further boosting market penetration across urban and rural areas.
  
• For instance, ACON Laboratories' HealthyMe UTI Test Strips are a home-use diagnostic solution designed for quick and reliable screening of urinary tract infections. These FDA-cleared and CE-marked strips detect key indicators, such as leukocytes and nitrites, and deliver results in just 2 minutes. The product is designed for individuals seeking discreet and convenient testing without the need to visit a clinic.
  
• Thus, the development of such kits accelerates the adoption in the home care setting, fostering the segment's growth.
  

Based on application, the urinary tract infection testing market, is segmented into urethritis, cystitis, and pyelonephritis. The cystitis segment accounted for the highest market share of 52.1% in 2024.

• Cystitis, an inflammation of the bladder, is the most frequently occurring UTI condition and disproportionately affects women because of anatomical differences. Many individuals often have recurrent cystitis, which leads to further testing and demand for diagnostic options.
  
• For instance, as per the data published in the Lancet Journal, around 10 to 60% of women annually suffer from uncomplicated cystitis at least once in their lifetime. Thus, as the prevalence of cystitis increases, so does the demand for accurate and technologically advanced diagnostic kits, fostering market growth.
  
• Moreover, public health campaigns and educational efforts have improved awareness of symptoms of cystitis, further encouraging early testing and treatment, contributing to the segment’s growth.
  

Based on end use, the urinary tract infection testing market is segmented into hospitals, diagnostic laboratories, homecare settings, and other end users. The hospitals segment accounted for the highest market share of 35.2% in 2024.

• Hospitals serve as the primary point of care for diagnosing complex urinary tract infections and addressing challenges with recurrent and severe urinary tract infections, offering the most comprehensive approach to diagnostic and treatment services. This enables patients to access both emergency services and routine monitoring of their urinary tract health.
  
• This healthcare settings dominate the urinary tract infection testing market because of the ability to accommodate a large volume of patients with their various healthcare services, including urine cultures, antimicrobial susceptibility testing, the ability to monitor patients' post-treatment outcomes, and the capacity to perform surgical procedures.
  
• Furthermore, urinary tract infection testing within a hospital is supported by medically trained staff with specializations in urology (urologists), infectious diseases, along with trained nursing personnel, resulting in accurate and timely management of urinary tract infections.
  

North America dominated the global urinary tract infection testing market, with the highest market share of 36.4% in 2024. This growth is highly attributed due to the region’s advanced healthcare infrastructure, and high rate of adoption of innovative medical technologies. Further, increasing prevalence of urinary tract infections in the U.S. and Canada, propelling the growth of market in the region.

• The U.S. urinary tract infection testing market was valued at 296.5 million and USD 324.1 million in 2021 and 2022, respectively. In 2024 the market size reached USD 348.4 million from USD 335.5 million in 2023.
  
• The rising incidence of urinary tract infections in the U.S., particularly among women, older individuals, and those with chronic illnesses such as diabetes, is positively influencing the market.
  
• For instance, according to the 2023 report published by the National Institutes of Health, over 10% of the female population in the U.S. is diagnosed annually with UTI, and more than 60% experience it at least once in their lifetime.
  
• Moreover, in the U.S., urinary tract infections (UTIs) represent a significant healthcare concern. Each year, they account for approximately 10.5 million office visits, 3 million emergency department visits, and 400,000 hospitalizations. Thus, as the prevalence of UTI increases in the region, so does the demand for accurate UTI diagnostic kits, accelerating market growth.
  

Europe urinary tract infection testing market accounted for USD 276.7 million in 2024 and is anticipated to show lucrative growth over the forecast period.

• The growth of the market in the region is highly attributed due to the rising prevalence of diabetes. Individuals suffering from diabetes are more prone to UTI infection. For instance, as per the data from World Health Organization (WHO), 74 million adults, and around 300,000 children and adolescents are living with diabetes in the WHO European Region. Thus, as the prevalence of diabetes increases, the risk of UTI infection among the diabetic patients, propelling the need for effective diagnostic tools such as urinary tract infection testing kits.
  
• Moreover, Germany, France, and the UK are among the leading countries in Europe driving the adoption of advanced diagnostic technologies for urinary tract infections. These nations are integrating point of care infectious disease testing which is estimated to reach USD 5.9 billion by 2032, such as rapid UTI testing solutions across hospitals, clinics, and diagnostic labs to improve early detection and treatment outcomes. Government-supported healthcare initiatives and collaborations with private diagnostic firms are enhancing accessibility and innovation, strengthening Europe’s position in the UTI testing market and contributing to its steady regional growth.
  

The UK urinary tract infection testing market is projected to experience steady growth between 2025 and 2034.

• The growth of the market is anticipated to be bolstered by the rising cases of diabetes across the UK. For instance, according to the British Diabetic Association, about 5.8 million people in the UK are living with diabetes. Thus, as the prevalence of diabetes increases, so does the rise of UTI among the affected population, fostering the demand for technologically advanced diagnostic kits.
  
• Moreover, the growth of the market in this region is anticipated to be strengthened by the UK government's commitment towards promoting awareness related to early disease diagnosis via initiatives such as public health campaigns and guidelines, further propelling industry expansion.
  

Asia Pacific region is projected to be valued at USD 277.8 million in 2025 and is expected to reach USD 516.4 million by 2034.

• The urinary tract infection testing market in the region is growing exponentially with rising awareness of urological health, rising elderly population, and growing healthcare infrastructure, particularly in countries such as India, China, and Japan.
  
• These regions are experiencing a high prevalence of urinary tract infections due to high population growth, increased patient pool of diabetes, and high rate of hospitalization, which leads to the risk of hospital-acquired infection, further propelling the market growth in the region.
  

Japan urinary tract infections testing market is poised to witness lucrative growth between 2025 – 2034.

• Japan has one of the fastest aging populations globally. As per estimates, Japan has around 36.25 million people aged 65 years and above, which leads to one-third of the entire Japanese population.
  
• Thus, this demographic shift has created awareness among healthcare providers and policymakers for the need for effective strategies to overcome infectious diseases such as urinary tract infection and their related health conditions, thereby propelling the adoption of advanced urinary tract infection testing solutions for early disease diagnosis, stimulating the market growth in the country. 
  

Brazil is experiencing significant growth in the urinary tract infections testing market.

• Brazil has one of the highest diabetes burdens in the region; the number of type 1 and type 2 diabetes cases is increasing, contributing to a rise in UTI incidence. Growing awareness and enhanced diagnostic capabilities are facilitating earlier detection and treatment.
  
• The country's healthcare system is increasingly adopting advanced diagnostic technologies, preventive care, and telemedicine-based follow-up care, particularly in urban centers. These technologies are helping to reduce hospitalizations and improve patient outcomes.
  

The urinary tract infections testing market in Saudi Arabia is expected to experience significant and promising growth from 2025 to 2034.

• Saudi Arabia's well-established healthcare infrastructure, coupled with increasing investments in advanced healthcare technologies, is driving the development and adoption of advanced diagnostic kits designed to meet the specific needs of the country's patient population suffering from UTI.
  
• Additionally, growing awareness about the significance of early and accurate diagnosis of infectious diseases across various age groups is further fueling market growth in the region.
  

Urinary Tract Infection Testing Market Share

• Key players, including Thermo Fisher Scientific, Randox Laboratories, F. Hoffmann-La Roche, LabCorp, and Siemens Healthineers, collectively hold 27.6% of the global market share. These companies maintain their leadership through diverse product portfolios, strategic collaborations, regulatory approvals, and ongoing innovation. LabCorp stands out due to their comprehensive range of testing, widely adopted in various healthcare settings.
  
• Thermo Fisher Scientific and have strengthened their market positions through partnership and regulatory approvals. In November 2023, Thermo Fisher Scientific and Flagship Pioneering announced a strategic partnership aimed at jointly creating new platform companies featuring first-in-class enabling technologies for the life sciences sector. This collaboration leveraged the strengths of both organizations, Thermo Fisher’s expertise in diagnostics and services, and Flagship’s innovation-driven approach to biotechnology to drive advancements in scientific discovery and healthcare solutions. The partnership provided a competitive edge in the diagnostics market, positioning both companies to capitalize on emerging opportunities and deliver enhanced value to their stakeholders.
  

Urinary Tract Infection Testing Market Companies

Few of the prominent players operating in the urinary tract infection testing industry include:

• Abbott Laboratories
• ACON Laboratories
• Bio-Rad Laboratories
• Cardinal Health
• F. Hoffmann-La Roche
• Focus Laboratories
• Labcorp
• Mankind
• Quest Diagnostics
• Randox Laboratories
• Siemens Healthineers
• Thermo Fisher Scientific
  
• F. Hoffmann-La Roche

F. Hoffmann-La Roche maintains a strong global presence, operating in over 100 countries and supported by an extensive network of distributors. This robust distribution network significantly enhances the company's market reach and accessibility.

• Abbott Laboratories

Abbott Laboratories maintains a robust product portfolio, driving widespread adoption and contributing to significant market growth.

• Thermo Fisher Scientific

Thermo Fisher Scientific is known for its expertise in diagnostics. The company offers highly accurate detection kits, leveraging its strong research and development capabilities to enhance sensitivity and reliability in results.

Urinary Tract Infection Testing Industry News:

• In September 2024, Mankind launched RAPID NEWS self-test kits, designed to address prevalent health concerns such as dengue, urinary tract infections (UTIs), and early menopause. This launch marked a pivotal step toward accessible healthcare, aiming to empower individuals across India with convenient, private, and rapid testing solutions. The product launch gave the company a competitive edge in the market, strengthening its position in the diagnostic segment and reinforcing its commitment to public health innovation.
  

The urinary tract infection testing market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Test Type

• Urinalysis
• Urine cultures
• Susceptibility testing

Market, By Test Kit Type

• Laboratory test kits
• Home test kits

Market, By Application

• Urethritis
• Cystitis
• Pyelonephritis

Market, By End Use

• Hospitals
• Diagnostic laboratories
• Homecare settings
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE